Please login to the form below

Not currently logged in
Email:
Password:

Celyad

This page shows the latest Celyad news and features for those working in and with pharma, biotech and healthcare.

CAR-T cancer therapy passes milestone

CAR-T cancer therapy passes milestone. Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses. ... A CAR-T therapy for leukaemia developed by Belgian biotech company Celyad has cleared a safety assessment and will now be tested

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy. Licence, option.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse; and Celyad's C-Cure, based on autologous cardiac stem cells.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Celyad appoints Dr David Gilham as R&D vice president Celyad appoints Dr David Gilham as R&D vice president

    Belgian biopharmaceutical company Celyad has selected Dr David Gilham to be its new vice president of research and development. ... group. Dr Gilham said: “ I am truly excited to be joining Celyad at such an important time in its history. “

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics